GLP-3 RT 20mg
Triple receptor metabolic research peptide
Certificate of Analysis
Testing performed in USA laboratories. All analytical data verified by third-party testing facilities.
COAs available upon request. Contact us for detailed certificates of analysis for specific batches.
How It Works
GLP3-R works by simultaneously activating three important hormone receptors: GLP-1, GIP, and glucagon receptors, creating a comprehensive metabolic response that surpasses single-pathway approaches.
Triple-Receptor Activation
GLP-1 Receptor
Triggers insulin release when blood sugar is high, slows stomach emptying, and reduces appetite signals.
GIP Receptor
Enhances insulin response and influences fat metabolism pathways for improved metabolic efficiency.
Metabolic Benefits
Glucagon Receptor
Helps the body burn stored fat for energy and maintains healthy blood sugar levels between meals.
Synergistic Effect
The triple-action approach creates a comprehensive metabolic response more effective than single-pathway targeting.
Research Findings
Preclinical research has demonstrated GLP3-R's remarkable potential across multiple metabolic research domains, showing superior outcomes compared to single-receptor approaches.
Weight Management Studies
Preclinical research has demonstrated significant weight reduction in laboratory models with dose-dependent effects and synergistic triple-receptor mechanisms.
- ▸ Significant weight reduction in laboratory models
- ▸ Dose-dependent effects with higher doses showing greater outcomes
- ▸ Synergistic effects surpassing single or dual-receptor agonists
- ▸ Sustained weight management over extended periods
Metabolic Health Research
Laboratory investigations have revealed comprehensive improvements across multiple metabolic markers and pathways in research models.
- ▸ Enhanced glucose homeostasis and insulin sensitivity
- ▸ Improved lipid profiles in research models
- ▸ Reduced inflammatory markers
- ▸ Better energy expenditure patterns
Comparative Studies
When compared to other GLP-1 receptor agonists, GLP3-R has demonstrated superior outcomes in weight reduction and metabolic improvements.
- ▸ Superior weight reduction compared to single-receptor compounds
- ▸ Enhanced metabolic improvements beyond GLP-1 alone
- ▸ Addition of GIP and glucagon activation provides unique benefits
- ▸ Improved therapeutic potential in research settings
Clinical Translation Research
Phase 2 trials have shown promising results for obesity and type 2 diabetes applications with significant clinical improvements.
- ▸ Phase 2 trial results showing substantial weight loss
- ▸ Improved glycemic control in diabetes research
- ▸ Cardiovascular and metabolic benefits
- ▸ Potential for transforming metabolic disorder treatment
IMPORTANT: This product is exclusively for laboratory research purposes and is not approved for human or veterinary use.